Open issues [🇷 for BE/BA]

posted by PharmCat  – Russia, 2020-08-07 13:29 (1414 d 05:28 ago) – Posting: # 21830
Views: 14,364

Hi ElMaestro!

I thought you asked about p, sorry :)

❝ Xi is the design matrix for fixed effects for the i'th subject.

❝ Thus is has a rank of max 3 and never more. This means we can at most use it to work with three parameter estimates. For example an intercept, a treatment effect, a period effect (within any given subject).


I think Xi is not shuld be full-rank design matrix. It is just part of X for subject i. Moreover all Xi should be the same width (num of columns) for Σ(Xi'V-1Xi). Also with (yi - Xi*β) you get residuals ri (col num of Xi should be equal length β).
There is not very accurate description in Gurka's paper, but it provide good concept.
If you check, it should work.

Complete thread:

UA Flag
Activity
 Admin contact
23,059 posts in 4,841 threads, 1,665 registered users;
30 visitors (0 registered, 30 guests [including 5 identified bots]).
Forum time: 18:57 CEST (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5